"We're working as fast as we can with the third party. Ultimately, it's the third party's responsibility to provide answers to those questions to the FDA. I think we're trying to provide realistic guidance, given that we're in a pandemic, of Q2 to Q3. And then it will be up to the FDA ultimately to determine if they still want an in-person inspection, when they want to conduct that inspection and how long they take to complete that process and the review. I mean, those are the facts as we know them, and we'll continue to work as fast as we can to get this medicine approved in the US and launched."